It was also reported that tanshinone IIA may be effective in overcoming doxorubicin resistance in MCF-7 cells of breast cancer, which was achieved by blocking the PI3K/AKT axis and reducing levels of ABC transporter proteins, including MRP1, P-gp, and BCRP (Li et al., 2019). This evidence concerns the gene ABCG2 and breast carcinoma.